LPTX - Leap Therapeutics Inc

LPTX - Leap Therapeutics Inc

https://www.leaptx.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - Leap Therapeutics ( NASDAQ:LPTX )

Benzinga • 5 months, 2 weeks ago • score: -0.31

In MSS colorectal cancer, sirexatamab's combo therapy showed a 32% higher ORR, 3.5-month longer PFS in high DKK1 patients vs. control. Patients without prior anti-VEGF therapy saw a 22% higher ORR and 2.6-month longer PFS with sirexatamab vs. control. Pelosi's latest AI pick skyrocketed 169% in ...

This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Apple ( NASDAQ:AAPL ) , Datadog ( NASDAQ:DDOG )

Benzinga • 7 months, 2 weeks ago • score: 0.19

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Oppenheimer analyst Martin Yang downgraded the rating for Apple Inc.

Here's Why Leap Therapeutics ( LPTX ) is Poised for a Turnaround After Losing -28.92% in 4 Weeks

Zacks Commentary • 1 year, 5 months ago • score: 0.14

Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.

52W High

$4.79

52W Low

$0.22

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.22

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.47

EV/Revenue (<3 favorable)

1.90

P/S (TTM) (<3 favorable)

160.10

P/B (<3 favorable)

2.05

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

16.21%

Institutions (25–75% balanced)

22.06%

Shares Outstanding

41,439,500

Float

34,665,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

375,000

Gross Profit (TTM)

1,500,000

EPS (TTM)

-1.58

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.84%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0073

Previous

-0.0093

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025